相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects
Pascale Fouqueray et al.
CLINICAL PHARMACOKINETICS (2020)
Mechanistic invitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (MATE) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetidine, trimethoprim or pyrimethamine
Robert Elsby et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2017)
The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects
Ivy H. Song et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2016)
Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration
D. Detaille et al.
CELL DEATH DISCOVERY (2016)
Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure
Robert Elsby et al.
DRUG METABOLISM AND DISPOSITION (2016)
Abundance of Drug Transporters in the Human Kidney Cortex as Quantified by Quantitative Targeted Proteomics
Bhagwat Prasad et al.
DRUG METABOLISM AND DISPOSITION (2016)
Imeglimin Normalizes Glucose Tolerance and Insulin Sensitivity and Improves Mitochondrial Function in Liver of a High-Fat, High-Sucrose Diet Mice Model
Guillaume Vial et al.
DIABETES (2015)
Characterization of Organic Anion Transporter 2 (SLC22A7): A Highly Efficient Transporter for Creatinine and Species-Dependent Renal Tubular Expression
Hong Shen et al.
DRUG METABOLISM AND DISPOSITION (2015)
The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
Pascale Fouqueray et al.
DIABETES CARE (2013)
Understanding the Critical Disposition Pathways of Statins to Assess Drug-Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1
R. Elsby et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients
V. Pirags et al.
DIABETES OBESITY & METABOLISM (2012)
Flip-flop pharmacokinetics - delivering a reversal of disposition: challenges and opportunities during drug development
Jaime A. Yanez et al.
THERAPEUTIC DELIVERY (2011)
Functional involvement of organic cation transporter1 (OCT1/Oct1) in the hepatic uptake of organic cations in humans and rats
K.-I. Umehara et al.
XENOBIOTICA (2007)
Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2
Satohiro Masuda et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Metformin transport by renal basolateral organic cation transporter hOCT2
N Kimura et al.
PHARMACEUTICAL RESEARCH (2005)
分享论文
